Stocks of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded higher last session on Wall Street, down -3.70% to $745.20.
According to the data, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has 27 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $1011.00 and a low of $605.00, we find $854.50. Given the previous closing price of $773.85, this indicates a potential upside of 10.42 percent. REGN stock price is now 0.48% away from the 50-day moving average and 8.46% away from the 200-day moving average. The market capitalization of the company currently stands at $80.38B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
A total of 8 analysts have issued a hold rating and 14 have given it a buy rating. Brokers who have rated the stock have averaged $841.68 as their price target over the next twelve months.
With the price target enhanced from $775 to $875, Cowen Upgraded its rating from Market Perform to Outperform for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). On January 20, 2023, JP Morgan Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock keeping its target price maintained at $850, while ‘Raymond James’ rates the stock as ‘Underperform’.
In other news, McCourt Marion, EVP Commercial sold 1,100 shares of the company’s stock on Mar 01. The stock was sold for $835,879 at an average price of $759.89. Upon completion of the transaction, the EVP Commercial now directly owns 20,803 shares in the company, valued at $15.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, Director RYAN ARTHUR F sold 100 shares of the business’s stock. A total of $76,250 was realized by selling the stock at an average price of $762.50. This leaves the insider owning 19,147 shares of the company worth $14.27 million. Insiders disposed of 583,537 shares of company stock worth roughly $434.85 million over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in REGN stock. A new stake in Regeneron Pharmaceuticals Inc. shares was purchased by ARDEVORA ASSET MANAGEMENT LLP during the first quarter worth $68,658,000. ALYESKA INVESTMENT GROUP, L.P. invested $54,373,000 in shares of REGN during the first quarter. In the first quarter, HOLOCENE ADVISORS, LP acquired a new stake in Regeneron Pharmaceuticals Inc. valued at approximately $53,786,000. HARVEST PORTFOLIOS GROUP INC. acquired a new stake in REGN for approximately $44,312,000. CAPITAL GROUP INVESTMENT MANAGEMENT PTE. LTD. purchased a new stake in REGN valued at around $30,792,000 in the second quarter. In total, there are 1,641 active investors with 89.50% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $774.13 for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). During the past 12 months, Regeneron Pharmaceuticals Inc. has had a low of $538.01 and a high of $800.48. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 5.10, and a quick ratio of 4.30. The fifty day moving average price for REGN is $741.90 and a two-hundred day moving average price translates $687.51 for the stock.
The latest earnings results from Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) was released for Dec, 2022. According to the Biotechnology Company, earnings per share came in at $12.56, beating analysts’ expectations of $10.03 by 2.53. This compares to $19.58 EPS in the same period last year. The net profit margin was 35.60% and return on equity was 20.50% for REGN. The company reported revenue of $3.41 billion for the quarter, compared to $4.95 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -31.05 percent. For the current quarter, analysts expect REGN to generate $3B in revenue.
Regeneron Pharmaceuticals Inc.(REGN) Company Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Leave a Reply